| Literature DB >> 34178633 |
Yuzhu Zhang1,2,3, Yang Sun1,2, Dongmei Li4, Xiaoyuan Liu1,2, Chen Fang1,2, Chunmin Yang1,2, Tianyu Luo1,2, Hai Lu1,2, Huachao Li1,2, Hongyan Zhang1,2, Qianyi Liang1,2, Jiahua Wu1,2, Limei Huang1,2, Rui Xu1,2, Liping Ren1,2, Qianjun Chen1,2.
Abstract
ABSTRACT: The present systematic review and meta-analysis was undertaken to evaluate the effects of acupuncture in women with breast cancer (BC), focusing on patient-reported outcomes (PROs).Entities:
Keywords: acupuncture; breast cancer; meta-analysis; patient-reported outcome; systematic review
Year: 2021 PMID: 34178633 PMCID: PMC8222976 DOI: 10.3389/fonc.2021.646315
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1The PRISMA 2009 flow diagram for literature screening. RCTs randomized controlled trials.
The QoL of acupuncture versus comparators for BC treatment-related symptoms.
| Outcome or Subgroup | Participants | End of treatment | Extended follow-up time | Meaning of higher scores | ||
|---|---|---|---|---|---|---|
| IV, Random, 95% CI | P value | IV, Random, 95% CI | P value | |||
| QLQ-C30_quality of life subscale ( | 154 | MD 10.09 [7.26, 12.92] | P<0.0001* | MD 8.81 [5.77, 11.85] | P<0.0001* | better |
| Simplified and modified QLQ-C30 ( | 30 | MD -1.10 [-1.25, -0.95] | P<0.0001* | NA | NA | worse |
| EuroQoL (EQ-5D) ( | 47 | NA | P=0.14 | NA | NA | better |
| FACT-G/B ( | ||||||
| Global ( | 32 | NA | NS | NA | NA | better |
| Physical well-being ( | 345 | MD 4.40 [1.49, 7.30] | P=0.003* | NA | NA | better |
| Social/family well-being ( | 345 | MD 1.02 [0.01, 2.04] | P=0.05 | NA | NA | better |
| Emotional well-being ( | 345 | MD 2.03 [1.11, 2.95] | P<0.0001* | NA | NA | better |
| Functional well-being ( | 345 | MD 3.49 [2.36, 4.62] | P<0.0001* | NA | NA | better |
| FACT-TAX ( | 63 | MD -1.40 [-11.74, 8.94] | P=0.79 | MD -4.50 [-16.99, 7.99] | P=0.48 | better |
| FACT-NTX subscale ( | 103 | MD 4.40 [-1.58, 10.37] | P=0.15 | MD -0.60 [-5.14, 3.94] | P=0.80 | better |
| FACT-ES ( | 226 | MD 3.26 [0.75, 5.77] | P=0.01* | MD 4.58 [1.85, 7.31] | P=0.001* | better |
| RR 2.04 [1.30, 3.20] | P=0.002* | RR 1.88 [1.22, 2.90] | P=0.004* | better | ||
| FACT-COG QoL subscale ( | 93 | MD 1.95 [-0.69, 4.60] | P=0.15 | NA | NA | better |
| MENQOL ( | ||||||
| Global ( | 50 | NA | NS | NA | NS | worse |
| Physical score ( | 190 | MD -0.50 [-0.91, -0.09] | P=0.02* | MD -0.50 [-0.92, -0.08] | P=0.02* | worse |
| Sexual score ( | 190 | MD -0.30 [-0.93, 0.33] | P=0.35 | MD -0.55 [-1.17, 0.07] | P=0.08 | worse |
| Vasomotor score ( | 190 | MD -1.50 [-1.93, -1.07] | P<0.00001* | MD -1.38 [-1.88, -0.88] | P<0.00001* | worse |
| Psychosocial score ( | 190 | MD -0.60 [-1.09, -0.11] | P=0.02* | MD -0.71 [-1.22, -0.20] | P=0.006* | worse |
| WHQ ( | 45 | RR 1.52 [0.79, 2.94] | P=0.21 | 0.85 [0.51, 1.42] | P=0.53 | better |
| PGWB ( | 45 | NA | NA | NA | P=0.19 | better |
*P < 0.05. QLQ-C30, Quality-of-Life Questionnaire Core 30; EuroQol(EQ-5D), European quality-of-life survey; FACT-G/B, Functional Assessment of Cancer Therapy–General/Breast; FACT-TAX, The Functional Assessment of Cancer Therapy-Taxane (FACT-TAX); FACT-NTX subscale, Functional Assessment of Cancer Therapy-Neurotoxicity subscale; FACT-ES, Functional Assessment of Cancer Therapy-Endocrine Symptoms; FACT-COG, Functional Assessment Of Cancer Treatment Cognition Test; MENQOL, Menopause-Specific Quality of Life Questionnaire; WHQ, Women’s Health Questionnaire; PGWB, Psychological and General Well-being Index; NA, Not available; NS, Not significant; RR, Risk Ratio; MD, Mean Difference; IV, Inverse Variance; CI, Confidence Interval.
Figure 2Forest plot of the change of pain in BC patients treated with acupuncture and control from the bassline to end of treatment. (A) Pain measured by Brief Pain Inventory-Short Form; (B) Pain measured by Visual Analogue Scale. IV, inverse variance; CI, Confidence Interval. The Roman numerals “I” followed the study ID represented the comparison of acupuncture versus no intervention in the study which had three arms.
Figure 3Forest plot of the change of hot flashes in BC patients treated with acupuncture and control from the bassline to end of treatment. IV, inverse variance; CI, Confidence Interval. The Roman numerals “I” and “II” followed the study ID represented the comparison of acupuncture versus no intervention and the comparison of acupuncture versus western medicine, respectively, in the study which had four arms.
Figure 4Forest plot of the change of fatigue in BC patients treated with acupuncture and control from the bassline to end of treatment. IV, inverse variance; CI, Confidence Interval. The Roman numerals “I” followed the study ID represented the comparison of acupuncture versus no intervention in the study which had three arms.
Figure 5Forest plot of sleep disturbances in BC patients treated with acupuncture and control. (A) the changes in mean scores of sleep disturbances from the bassline to end of treatment; (B) Number of patients with sleep disturbance at the end of treatment. IV, inverse variance; CI, Confidence Interval. The Roman numerals “I” followed the study ID represented the comparison of acupuncture versus no intervention in the study which had three arms.
Figure 6Forest plot of the change of anxiety and depression in BC patients treated with acupuncture and control from the bassline to end of treatment. IV, inverse variance; CI, Confidence Interval. The Roman numerals “I” followed the study ID represented the comparison of acupuncture versus no intervention in the study which had three arms.
The effect of acupuncture on the QoL compared to different comparators.
| Outcome or Subgroup | Participants | End of treatment | Meaning of higher scores | |
|---|---|---|---|---|
| IV, Random, 95% CI | P value | |||
|
| ||||
| QLQ-C30_quality of life subscale ( | 104 | MD 10.10 [7.10, 13.10] | P<0.0001* | better |
| EuroQoL (EQ-5D) scale ( | 47 | NA | P=0.14 | better |
| FACT-G global scale ( | 32 | NA | NS | better |
| FACT-G Physical well-being subscale ( | 43 | MD 6.40 [2.93, 9.87] | P=0.0003* | better |
| FACT-G Social/family well-being subscale ( | 43 | MD 0.70 [-2.86, 4.26] | P=0.70 | better |
| FACT-G Emotional well-being subscale ( | 43 | MD 3.00 [0.00, 6.00] | P=0.05 | better |
| FACT-G Functional well-being subscale ( | 43 | MD 2.80 [-0.70, 6.30] | P=0.12 | better |
| FACT-TAX scale ( | 63 | MD -1.40 [-11.74, 8.94] | P=0.79 | better |
| FACT-NTX subscale ( | 63 | MD 1.40 [-2.87, 5.67] | P=0.52 | better |
| FACT-ES scale ( | 169 | MD -3.38 [-6.92, 0.16] | P=0.06 | better |
| FACT-ES scale** ( | 169 | RR 1.89 [1.03, 3.48] | P=0.04 | better |
|
| ||||
| QLQ-C30_quality of life subscale ( | 40 | MD 7.50 [2.94, 12.06] | P=0.001* | better |
| FACT-G Physical well-being subscale ( | 302 | MD 3.30 [2.17, 4.43] | P< 0.001* | better |
| FACT-G Social/family well-being subscale ( | 302 | MD 1.05 [-0.01, 2.11] | P=0.05 | better |
| FACT-G Emotional well-being subscale ( | 302 | MD 1.93 [0.96, 2.90] | P< 0.001* | better |
| FACT-G Functional well-being subscale ( | 302 | MD 0.61 [2.38, 4.76] | P< 0.001* | better |
| FACT-ES scale ( | 167 | MD -3.14 [6.69, 0.41] | P=0.08 | better |
| FACT-ES scale** ( | 167 | RR 2.24 [1.14, 4.42] | P=0.02* | better |
| FACT-COG QoL subscale ( | 93 | MD 1.95 [-0.69, 4.60] | P=0.15 | better |
| MENQOL Physical score ( | 190 | MD -0.50 [-0.91, -0.09] | P=0.02* | worse |
| MENQOL Sexual score ( | 190 | MD -0.30 [-0.93, 0.33] | P=0.35 | worse |
| MENQOL Vasomotor score ( | 190 | MD -1.50 [-1.93, -1.07] | P<0.00001* | worse |
| MENQOL Psychosocial score ( | 190 | MD -0.60 [-1.09, -0.11] | P=0.02* | worse |
|
| ||||
| Simplified and modified QLQ-C30 ( | 30 | MD -1.10 [-1.25, -0.95] | P<0.0001* | worse |
| MENQOL global scale ( | 50 | NA | NS | worse |
| WHQ ( | 45 | RR 1.52 [0.79, 2.94] | P=0.21 | better |
| PGWB ( | 45 | NA | NA | better |
*P < 0.05.
**Proportion with >30% Improvement.
QLQ-C30, Quality-of-Life Questionnaire Core 30; EuroQol(EQ-5D), European quality-of-life survey; FACT-G/B, Functional Assessment of Cancer Therapy–General/Breast; FACT-TAX, The Functional Assessment of Cancer Therapy-Taxane (FACT-TAX); FACT-NTX subscale, Functional Assessment of Cancer Therapy-Neurotoxicity subscale; FACT-ES, Functional Assessment of Cancer Therapy-Endocrine Symptoms; FACT-COG, Functional Assessment Of Cancer Treatment Cognition Test; MENQOL, Menopause-Specific Quality of Life Questionnaire; WHQ, Women’s Health Questionnaire; PGWB, Psychological and General Well-being Index; NA, Not available; NS, Not significant; RR, Risk Ratio; MD, Mean Difference; IV, Inverse Variance; CI, Confidence Interval.
The effect of acupuncture on the secondary outcomes compared to different comparators.
| Outcome or Subgroup | Participants | End of treatment | Meaning of higher scores | |
|---|---|---|---|---|
| IV, Random, 95% CI | P value | |||
|
| ||||
| 1.1 Pain | ||||
| BPI-SF worst pain subscale ( | 275 | MD -1.84 [-3.59, -0.08] | P=0.04* | worse |
| BPI-SF average pain subscale ( | 169 | MD -0.70 [-1.26, -0.14] | P=0.01* | worse |
| BPI-SF pain interference subscale ( | 256 | MD -0.79 [-1.87, 0.28] | P=0.15 | worse |
| BPI-SF pain severity subscale ( | 256 | MD -1.28 [-3.35, 0.80] | P=0.23 | worse |
| BPI-SF worst stiffness subscale ( | 169 | MD -1.10 [-1.82, -0.38] | P=0.003* | worse |
| 1.2 Hot flashes | ||||
| Hot flashes score ( | 62 | MD -1.50 [-5.05, 2.05] | P=0.41 | worse |
| Hot flashes frequency ( | 215 | MD -0.81 [-2.30, 0.67] | P=0.28 | worse |
| 1.3 Fatigue ( | 250 | SMD-0.27 [-0.52, -0.02] | P=0.04* | worse |
| 1.4 Sleep disturbances | ||||
| PSQI or QLQ-C30 sleep disturbance subscale ( | 239 | SMD -0.47 [-0.78, -0.17] | P=0.002* | worse |
| No. of pts with sleep disturbance ( | 60 | RR 0.53 [0.33, 0.88] | P=0.01* | worse |
| 1.5 Anxiety ( | 116 | MD -1.09 [-2.21, 0.03] | P=0.06 | worse |
| 1.6 Depression ( | 116 | MD -0.30 [-1.60, 0.99] | P=0.64 | worse |
|
| ||||
| 2.1 Pain | ||||
| BPI-SF worst pain subscale ( | 167 | MD -1.10 [-1.75, -0.45] | P=0.0009* | worse |
| BPI-SF average pain subscale ( | 207 | MD -1.09 [-2.04, -0.13] | P=0.03* | worse |
| BPI-SF pain interference subscale ( | 252 | MD -1.27 [-2.01, -0.54] | P=0.0007* | worse |
| BPI-SF pain severity subscale ( | 252 | MD -1.13 [-1.84, -0.43] | P=0.002* | worse |
| BPI-SF worst stiffness subscale ( | 167 | MD -1.00 [-1.63, -0.37] | P=0.002* | worse |
| VAS ( | 160 | SMD-0.83 [-1.16, -0.51] | P<0.00001* | worse |
| 2.2 Hot flashes | ||||
| Hot flashes score ( | 248 | MD -7.28 [-17.75, 3.20] | P=0.17 | worse |
| 2.3 Fatigue ( | 275 | MD -0.50 [-0.76, -0.25] | P<0.0001* | worse |
| 2.4 Sleep disturbances ( | 45 | MD -1.50 [-3.50, 0.50] | P=0.14 | worse |
| 2.5 Anxiety ( | 45 | MD -1.30 [-3.11, 0.51] | P=0.16 | worse |
| 2.6 Depression ( | 93 | MD -1.23 [-4.86, 2.39] | P=0.50 | worse |
|
| ||||
| 3.1 Hot flashes | ||||
| Hot flashes score ( | 60 | MD -2.20 [-5.59, 1.19] | P=0.20 | worse |
| 3.2 Sleep disturbances ( | 58 | MD -1.80 [-3.40, -0.20] | P=0.03* | worse |
|
| ||||
| 4.1 Hot flashes | ||||
| Hot flashes frequency ( | 38 | MD 0.40 [-1.96, 2.76] | P=0.74 | worse |
*P < 0.05.
**Proportion with >30% Improvement.
BPI-SF, Brief Pain Inventory-Short Form; VAS, Visual Analogue Scale; PSQI, Pittsburgh Sleep Quality Index; QLQ-C30, Quality-of-Life Questionnaire Core 30; RR, Risk Ratio; MD, Mean Difference; SMD, Standard Mean Difference; IV, Inverse Variance; CI, Confidence Interval.
The pooled analysis results of high-quality articles for all predefined outcomes.
| Outcome or Subgroup | Participants | End of treatment | Meaning of higher values | |
|---|---|---|---|---|
| IV, Random, 95% CI | P value | |||
|
| ||||
| 1.1. FACT-G | ||||
| Physical well-being ( | 43 | MD 6.40 [2.93, 9.87] | P=0.0003* | better |
| Social/family well-being ( | 43 | MD 0.70 [-2.86, 4.26] | P=0.70 | better |
| Emotional well-being ( | 43 | MD 3.00 [0.00, 6.00] | P=0.05 | better |
| Functional well-being ( | 43 | MD 2.80 [-0.70, 6.30] | P=0.12 | better |
| 1.2. FACT-ES ( | 169 | MD -3.38 [-6.92, 0.16] | P=0.06 | better |
| RR 1.89 [1.03, 3.47] ** | P=0.04* | better | ||
|
| ||||
| 2.1. BPI-SF | ||||
| Worst Pain ( | 269 | MD -2.24 [-4.79, 0.30] | P=0.08 | worse |
| Average Pain ( | 226 | MD -0.70 [-1.26, -0.14] | P=0.01* | worse |
| Pain Interference ( | 313 | MD -0.79 [-1.87, 0.28] | P=0.15 | worse |
| Pain Severity ( | 313 | MD -1.28 [-3.35, 0.80] | P=0.23 | worse |
| Worst Stiffness ( | 226 | MD -1.10 [-1.82, -0.38] | P=0.003* | worse |
|
| ||||
| 3.1. Hot flashes score ( | 64 | MD -1.50 [-5.05, 2.05] | P=0.41 | worse |
| 3.3.1 Hot flashes frequency ( | 215 | MD -0.81 [-2.30, 0.67] | P=0.28 | worse |
|
| ||||
| 4.1 BFI or PFS ( | 136 | SMD -0.34 [-0.68, -0.00] | P=0.05 | worse |
|
| ||||
| 5.1. PSQI ( | 125 | MD -1.10 [-2.52, 0.32] | P=0.13 | worse |
| 5.2. No. of pts with sleep disturbance ( | 60 | RR 0.53 [0.33, 0.88] | P=0.01* | worse |
|
| ||||
| 6.1. Anxiety ( | 116 | MD -0.35 [-0.72, 0.02] | P=0.23 | worse |
| 6.2. Depression ( | 116 | MD -0.08 [-0.44, 0.28] | P=0.67 | worse |
*p < 0.05.
**Proportion with >30% Improvement
FACT-G, Functional Assessment of Cancer Therapy–General; FACT-ES, Functional Assessment of Cancer Therapy-Endocrine Symptoms; BPI-SF, Brief Pain Inventory-Short Form; BFI, Brief Fatigue Inventory; PFS, Piper fatigue scale; PSQI, Pittsburgh Sleep Quality Index; pts, patients; NA, Not available; NS, Not significant; IV, Inverse Variance; CI, Confidence Interval.
The pooled analysis results of acupuncture versus comparators for BC treatment-related symptoms at extended follow up time.
| Outcome | PROM | Participants | Estimate of the effect | P value | Meaning of higher scores |
|---|---|---|---|---|---|
| Pain | BPI-SF worst pain subscale ( | 63 | MD 1.00, 95%CI [-0.28, 2.28] | P=0.13 | worse |
| BPI-SF pain interference subscale ( | 67 | MD -1.44, 95%CI [-2.61, -0.26] | P=0.02* | worse | |
| BPI-SF pain severity subscale ( | 67 | MD -1.42, 95%CI [-2.89, 0.05] | P=0.06 | worse | |
| Fatigue | BFI, PFS, QLQ-C30 fatigue subscale ( | 253 | SMD -0.34, 95%CI [-0.57, -0.10] | P=0.006* | worse |
| Sleep disturbance | QLQ-C30 sleep disturbance subscale, PSQI ( | 204 | SMD -0.31, 95%CI [-0.77, 0.14] | P=0.18 | worse |
| Anxiety | HADS-anxiety subscale ( | 67 | MD -1.94, 95%CI [-3.14, -0.74] | P=0.002* | worse |
| Depression | HADS-depression subscale ( | 67 | MD -0.80, 95%CI [-2.85, 1.26] | P=0.45 | worse |
*P < 0.05; BPI-SF, Brief Pain Inventory-Short Form; BFI, Brief Fatigue Inventory; PFS, Piper fatigue scale; QLQ-C30, Quality-of-Life Questionnaire Core 30; PSQI, Pittsburgh Sleep Quality Index; HADS, Hospital Anxiety and Depression Scale; RR, Risk Ratio; MD, Mean Difference; SMD, Standard Mean Difference; IV, Inverse Variance; CI, Confidence Interval.